These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Paraoxonase gene polymorphisms and haplotype analysis in a stroke population. Pasdar A; Ross-Adams H; Cumming A; Cheung J; Whalley L; St Clair D; MacLeod MJ BMC Med Genet; 2006 Mar; 7():28. PubMed ID: 16551349 [TBL] [Abstract][Full Text] [Related]
23. The Relevance of Noncoding DNA Variations of Paraoxonase Gene Cluster in Atherosclerosis-Related Diseases. Wysocka A; Zwolak A Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33670025 [TBL] [Abstract][Full Text] [Related]
24. An Engineered Version of Human PON2 Opens the Way to Understand the Role of Its Post-Translational Modifications in Modulating Catalytic Activity. Mandrich L; Cerreta M; Manco G PLoS One; 2015; 10(12):e0144579. PubMed ID: 26656916 [TBL] [Abstract][Full Text] [Related]
25. Paraoxonase-2 (PON2) in brain and its potential role in neuroprotection. Costa LG; de Laat R; Dao K; Pellacani C; Cole TB; Furlong CE Neurotoxicology; 2014 Jul; 43():3-9. PubMed ID: 24012887 [TBL] [Abstract][Full Text] [Related]
26. Paraoxonase 2 C311S single nucleotide polymorphism is associated with type C lesions in coronary atherosclerosis. Paszek E; Godlewski J; Wołkow P; Żmudka K; Słowik A; Legutko J; Kleczyński P Clin Biochem; 2022; 105-106():64-69. PubMed ID: 35460610 [TBL] [Abstract][Full Text] [Related]
27. WTAP and BIRC3 are involved in the posttranscriptional mechanisms that impact on the expression and activity of the human lactonase PON2. Carusone TM; Cardiero G; Cerreta M; Mandrich L; Moran O; Porzio E; Catara G; Lacerra G; Manco G Cell Death Dis; 2020 May; 11(5):324. PubMed ID: 32382056 [TBL] [Abstract][Full Text] [Related]
28. Codon 311 (Cys --> Ser) polymorphism of paraoxonase-2 gene is associated with apolipoprotein E4 allele in both Alzheimer's and vascular dementias. Janka Z; Juhász A; Rimanóczy A A; Boda K; Márki-Zay J; Kálmán J Mol Psychiatry; 2002; 7(1):110-2. PubMed ID: 11803456 [TBL] [Abstract][Full Text] [Related]
29. Increased PON lactonase activity in morbidly obese patients is associated with impaired lipid profile. Alaminos-Castillo MÁ; Ho-Plagaro A; García-Serrano S; Santiago-Fernandez C; Rodríguez-Pacheco F; Garrido-Sanchez L; Rodriguez C; Valdes S; Gonzalo M; Moreno-Ruiz FJ; Rodríguez-Cañete A; Montiel-Casado C; Garcia-Fuentes E Int J Clin Pract; 2019 Jun; 73(6):e13315. PubMed ID: 30681756 [TBL] [Abstract][Full Text] [Related]
30. Developmental expression of paraoxonase 2. Garrick JM; Dao K; de Laat R; Elsworth J; Cole TB; Marsillach J; Furlong CE; Costa LG Chem Biol Interact; 2016 Nov; 259(Pt B):168-174. PubMed ID: 27062895 [TBL] [Abstract][Full Text] [Related]
31. Pharmacogenetics of paraoxonases: a brief review. Draganov DI; La Du BN Naunyn Schmiedebergs Arch Pharmacol; 2004 Jan; 369(1):78-88. PubMed ID: 14579013 [TBL] [Abstract][Full Text] [Related]
32. Comparative modeling of PON2 and analysis of its substrate binding interactions using computational methods. Barathi S; Charanya M; Muthukumaran S; Angayarkanni N; Umashankar V J Ocul Biol Dis Infor; 2010 Jun; 3(2):64-72. PubMed ID: 22319641 [TBL] [Abstract][Full Text] [Related]
33. Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. Draganov DI; Teiber JF; Speelman A; Osawa Y; Sunahara R; La Du BN J Lipid Res; 2005 Jun; 46(6):1239-47. PubMed ID: 15772423 [TBL] [Abstract][Full Text] [Related]
34. Macrophage endoplasmic reticulum (ER) proteins and reducing elements stabilize paraoxonase 2 (PON2). Rosenblat M; Volkova N; Aviram M Atherosclerosis; 2010 Dec; 213(2):408-14. PubMed ID: 21036357 [TBL] [Abstract][Full Text] [Related]
35. Effect of certain non-steroidal anti-inflammatory drugs on the paraoxonase 2 (PON2) in human monocytic cell line U937. Solmaz Avcıkurt A; Korkut O Arch Physiol Biochem; 2018 Oct; 124(4):378-382. PubMed ID: 29199478 [TBL] [Abstract][Full Text] [Related]
36. Paraoxonase 1 activities and genetic variation in childhood obesity. Rupérez AI; López-Guarnido O; Gil F; Olza J; Gil-Campos M; Leis R; Tojo R; Cañete R; Gil A; Aguilera CM Br J Nutr; 2013 Nov; 110(9):1639-47. PubMed ID: 23789921 [TBL] [Abstract][Full Text] [Related]
37. PON2 subverts metabolic gatekeeper functions in B cells to promote leukemogenesis. Pan L; Hong C; Chan LN; Xiao G; Malvi P; Robinson ME; Geng H; Reddy ST; Lee J; Khairnar V; Cosgun KN; Xu L; Kume K; Sadras T; Wang S; Wajapeyee N; Müschen M Proc Natl Acad Sci U S A; 2021 Feb; 118(7):. PubMed ID: 33531346 [TBL] [Abstract][Full Text] [Related]
38. PON2 gene variants are associated with clinical manifestations of cardiovascular disease in familial hypercholesterolemia patients. Leus FR; Zwart M; Kastelein JJ; Voorbij HA Atherosclerosis; 2001 Feb; 154(3):641-9. PubMed ID: 11257265 [TBL] [Abstract][Full Text] [Related]
39. Human carotid lesion linoleic acid hydroperoxide inhibits paraoxonase 1 (PON1) activity via reaction with PON1 free sulfhydryl cysteine 284. Tavori H; Aviram M; Khatib S; Musa R; Mannheim D; Karmeli R; Vaya J Free Radic Biol Med; 2011 Jan; 50(1):148-56. PubMed ID: 21044882 [TBL] [Abstract][Full Text] [Related]
40. The risk of coronary artery disease in population of Taiwan is associated with Cys-Ser 311 polymorphism of human paraoxonase (PON)-2 gene. Pan JP; Lai ST; Chiang SC; Chou SC; Chiang AN Zhonghua Yi Xue Za Zhi (Taipei); 2002 Sep; 65(9):415-21. PubMed ID: 12433026 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]